Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials NEW YORK, NY--(Marketwired - May 7, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA...